Articles related to KIDNEY CANCER/RCC

Belzutifan’s FDA approval, following the LITESPARK-005 trial results, represents a significant stride in treating advanced kidney cancer, offering a novel therapeutic option for patients who have exhausted standard treatments.

A recent study from Fox Chase Cancer Center has revealed that as many as 23% of cystic renal masses may carry high-grade, or aggressive, disease. This finding challenges the prevailing assumption of their low-risk nature and underscores the need for more discerning diagnostic and treatment strategies.

Explore how the landscape of RCC treatment is evolving with a focus on inclusivity and patient-centric approaches.

Discover how SABR is setting a new standard in the treatment of inoperable renal cell carcinoma, offering exceptional cancer control with minimal side effects.

Understanding the impact of lymphovascular invasion on overall survival in RCC patients is crucial for surgical decision-making and postoperative care.

Innovations in mRCC management are accelerating, and significant shifts have already begun with the ODYSSEY RCC study and the first-ever comprehensive ASCO guidelines for metastatic clear-cell RCC – read on to stay ahead of the curve.